MRZM (Marizyme) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


MRZM Marizyme Inc MRZM
12 GF Score
Price $0.00
View Full Analysis

What is Marizyme Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Marizyme's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

MRZM vs CNBX, XSNX, NBIO: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Marizyme's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marizyme Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marizyme's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Marizyme's Margin of Safety % (DCF FCF Based) falls into.


MRZM
12GF Score
Marizyme Inc MRZM
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marizyme Business Description

Address 555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
12GF Score

Get the complete analysis for MRZM

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price